Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + pomalidomide + dexamethasone with carfilzomib in relapsed/refractory multiple myeloma
2019-001027-12Phase 2Active
- Sponsor
- CHU de Poitiers
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, pomalidomide, carfilzomib and dexamethasone in multiple myeloma (MM), sponsored by CHU de Poitiers. Primary endpoint: MRD 10^-5 incidence rate in patients achieving ≥VGPR. Started Jul 2019; status: active.
02
Drugs
isatuximabpomalidomidecarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-001027-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001027-12.